leisure time -WSS

leisure time

author：fashion 2025-09-06 06:17:21 - browse：37656

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Illinois Supreme Court finds assault weapons ban constitutional

Wikipedia

hotspot

WSS

Timeline: How the deadly wildfires took over Maui day by day

Will the FTC rein in IQVIA's health data empire?

Dems pitch expanding Medicare power to negotiate drug prices

Novo Nordisk touts Wegovy study, but still struggling with supply

Health AI: on the border between health care and tech

Mark Cuban is blaming the wrong people for high drug costs

focus

leisure time

Bluebird and the case for gene therapy profits

Wikipedia

At least 13 dead in Texas as scorching temps continue

Surge in Apellis stock fueled by confidence in safety of its eye drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bird flu researchers hone in on Finland’s mink farms

Activists slam private health insurers over coverage restrictions

Aspartame and sugar

Hollywood unions extend contract negotiations for actors

Dozens dead from Maui wildfires: What we know about the victims

Psychedelics group wrestles with new pharma identity

Be careful with at

Wikipedia

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

What to watch for from Zogenix and Amicus clinical trials

Hospitals are dialing back on venture capital investing

Hospitals are dialing back on venture capital investing

YouTube cracks down on misinformation on cancer treatment

Maui wildfire now ranks as the fifth

Wikipedia

knowledge

hotspot

hotspot